MedTrace Logo

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2850

Last updated 2018-04-05

No results posted yet for this study

Summary

Background:

\- The Baltimore Longitudinal Study of Aging (BLSA) is a long-term study of human aging. To see how the brain changes with age, researchers will study BLSA participants who are at least 60 years old. In particular, researchers are looking for early markers of possible Alzheimer's disease and other conditions that cause memory loss. To do so, they will give tests of memory and brain function, and stay in close contact with participants.

Objectives:

\- To study cognitive changes that occur in normal aging and in people who develop memory problems.

Eligibility:

\- Individuals at least 60 years of age who are participating in the BLSA.

Design:

* There are three parts to this study. These study procedures will be done under the usual BLSA guidelines.
* Participants will take paper and pencil tests. The tests measure skills such as language, attention, memory, and problem solving. They will also ask questions about emotions and feelings.
* Participants will give the name and phone number of a person who knows them well and sees them often. Researchers will ask this person to fill out questionnaires on the effects of aging on the participant. These questions will monitor the participant's memory and ability to function independently.
* Participants will have regular phone calls between study visits. These calls will help to keep their information up to date.
* Participants will continue on this study for as long as they are able to participate.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alan B Zonderman, Ph.D. · National Institute on Aging (NIA)

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-03-19
Primary Completion
2014-06-16
Completion
2015-01-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01867346 on ClinicalTrials.gov